ESSA Pharma Inc
EPIX1.880USD
0.000
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
83.45MCap. mercado
PérdidaP/E TTM
Más Datos de ESSA Pharma Inc Compañía
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Información de la empresa
Símbolo de cotizaciónEPIX
Nombre de la empresaESSA Pharma Inc
Fecha de salida a bolsaFeb 22, 2021
Director ejecutivoDr. David Ross Parkinson, M.D.
Número de empleados35
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 22
Dirección999 West Broadway, Suite 720
CiudadVANCOUVER
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísCanada
Código postalV5Z 1K5
Teléfono17783310962
Sitio Webhttps://www.essapharma.com/
Símbolo de cotizaciónEPIX
Fecha de salida a bolsaFeb 22, 2021
Director ejecutivoDr. David Ross Parkinson, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Richard M. Glickman, LL.D.
Dr. Richard M. Glickman, LL.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
51.70K
-14.06%
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
33.59K
+0.75%
Mr. Scott Requadt
Mr. Scott Requadt
Independent Director
Independent Director
30.00K
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
7.78K
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
5.12K
--
Ms. Marella Thorell
Ms. Marella Thorell
Independent Director
Independent Director
2.88K
--
Mr. Franklin M. Berger
Mr. Franklin M. Berger
Independent Director
Independent Director
--
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Director
Independent Director
--
--
Dr. David Ross Parkinson, M.D.
Dr. David Ross Parkinson, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Alex Martin
Mr. Alex Martin
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Richard M. Glickman, LL.D.
Dr. Richard M. Glickman, LL.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
51.70K
-14.06%
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
33.59K
+0.75%
Mr. Scott Requadt
Mr. Scott Requadt
Independent Director
Independent Director
30.00K
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
7.78K
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
5.12K
--
Ms. Marella Thorell
Ms. Marella Thorell
Independent Director
Independent Director
2.88K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BVF Partners L.P.
19.71%
Soleus Capital Management, L.P.
9.83%
Tang Capital Management, LLC
9.69%
BML Capital Management LLC
9.51%
Morgan Stanley & Co. LLC
9.46%
Other
41.80%
Accionistas
Accionistas
Proporción
BVF Partners L.P.
19.71%
Soleus Capital Management, L.P.
9.83%
Tang Capital Management, LLC
9.69%
BML Capital Management LLC
9.51%
Morgan Stanley & Co. LLC
9.46%
Other
41.80%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
46.19%
Investment Advisor
13.36%
Research Firm
11.99%
Corporation
3.77%
Investment Advisor/Hedge Fund
2.45%
Individual Investor
2.24%
Venture Capital
0.05%
Other
19.93%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
91
33.44M
75.34%
-17.34M
2025Q1
96
33.48M
75.44%
-17.56M
2024Q4
101
34.20M
77.05%
-15.63M
2024Q3
97
36.44M
82.10%
-7.65M
2024Q2
110
36.54M
82.36%
-10.99M
2024Q1
138
36.33M
81.91%
-11.35M
2023Q4
143
35.77M
81.03%
-12.57M
2023Q3
161
36.59M
82.99%
-18.42M
2023Q2
177
36.37M
82.51%
-21.24M
2023Q1
185
36.21M
82.14%
-19.98M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BVF Partners L.P.
8.75M
19.71%
--
--
Apr 09, 2025
Soleus Capital Management, L.P.
2.26M
5.1%
--
--
Apr 23, 2025
Tang Capital Management, LLC
4.30M
9.69%
--
--
Mar 31, 2025
BML Capital Management LLC
4.22M
9.51%
--
--
Apr 24, 2025
Morgan Stanley & Co. LLC
4.20M
9.46%
+10.76K
+0.26%
Mar 31, 2025
Opaleye Management Inc.
2.21M
4.98%
--
--
Mar 31, 2025
Pfizer Inc
1.68M
3.77%
--
--
Mar 31, 2025
Altium Capital Management LP
1.05M
2.37%
-377.63K
-26.44%
Mar 31, 2025
Berger (Franklin Milan)
784.40K
1.77%
--
--
Jan 08, 2025
BofA Global Research (US)
698.27K
1.57%
-114.04K
-14.04%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Avantis US Small Cap Equity ETF
0%
Avantis US Small Cap Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
